Who owns TAKWhat TAK owns
What Takeda Pharmaceutical Company Limited owns
The company's own 13F portfolio · as of 2025-09-30 · long US-listed stakes only — private holdings, bonds and cash are not disclosable on a 13F
$16.4M
disclosed stock portfolio
8
positions
59.8%
in Ovid
Positions, as of 2025-09-30
ordered by filed value · % of book = share of the disclosed stock portfolio · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | Ovid Therapeutics, Inc. | 7.5M | $9.8M | 59.8% |
| 2 | Equillium, Inc. | 1.8M | $2.6M | 15.9% |
| 3 | Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics) | 1.5M | $1.2M | 7.6% |
| 4 | Shattuck Labs, Inc. | 515,619 | $1.2M | 7.5% |
| 5 | Lyell Immunopharma, Inc. | 54,887 | $891,365 | 5.4% |
| 6 | American Well Corporation | 77,733 | $478,061 | 2.9% |
| 7 | Rani Therapeutics Holdings, Inc. | 203,190 | $101,554 | 0.6% |
| 8 | Standard Biotools, Inc. | 16,515 | $21,470 | 0.1% |
Source: SEC Form 13F-HR filed by TAKEDA PHARMACEUTICAL CO LTD (CIK 1395064), reporting period 2025-09-30. Values are quarter-end filed marks. Research, not investment advice.